Holen Sie sich die Stockscreener-App
34.17
2.61%
0.87
Schlusskurs vom Vortag:
$33.30
Offen:
$33.55
24-Stunden-Volumen:
42,683
Relative Volume:
0.14
Marktkapitalisierung:
$1.04B
Einnahmen:
$339.92M
Nettoeinkommen (Verlust:
$-12.83M
KGV:
-79.56
EPS:
-0.4295
Netto-Cashflow:
$4.52M
1W Leistung:
+3.08%
1M Leistung:
-4.58%
6M Leistung:
+36.79%
1J Leistung:
+42.61%
1-Tages-Spanne:
$33.19
$34.20
1-Wochen-Bereich:
$32.69
$34.72
52-Wochen-Spanne:
$17.72
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, NTRA, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
34.17 | 1.04B | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
693.62 | 256.47B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
231.88 | 163.00B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.76 | 59.21B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
177.69 | 50.10B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
463.31 | 45.52B | 3.77B | 449.25M | 240.68M | 7.8556 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-25 | Eingeleitet | Roth Capital | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences CEO Derek Maetzold sells $462,567 in stock - Investing.com
Castle Biosciences CEO Derek Maetzold sells $462,567 in stock By Investing.com - Investing.com Nigeria
Form 4 Castle Biosciences Inc: Derek J. Maetzold (Director, Pres. & Chief Exec. Officer) For: 19 October - Investing.com Nigeria
Form 144 Castle Biosciences For: 17 October By Investing.com - Investing.com Nigeria
Castle Biosciences CCO Tobin sells $110,608 in stock By Investing.com - Investing.com Nigeria
Form 4 Castle Biosciences Inc: Tobin W. Juvenal (Chief Commercial Officer) For: 12 October - Investing.com Nigeria
Castle Biosciences CCO Tobin sells $110,608 in stock - Investing.com
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 3,288 Shares - GuruFocus
Castle Biosciences CCO Tobin Juvenal Files to Sell 13,154 Shares in October 2026 - Kalkine Media
The chief commercial officer proposes selling 13,154 Castle Biosciences (CSTL) shares. - Stock Titan
Form 4 Castle Biosciences Inc For: 10 October By Investing.com - Investing.com South Africa
Castle Biosciences president and CEO Derek Maetzold sells $515k stock - Investing.com
Form 4 Castle Biosciences Inc For: 10 October By Investing.com - Investing.com Nigeria
Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Consensus Target Price of $42.00 According to Brokerages - MarketBeat
Castle Biosciences CEO Derek Maetzold Executes Option Exercise and Sells 14,496 Shares on October 5, 2026 - Kalkine Media
Castle Biosciences Officer Derek Maetzold Files Form 144 for 28,992 Share Sale Valued Over $1 Million - Kalkine Media
An officer and two trusts propose selling 28,992 shares of Castle Biosciences (CSTL). - Stock Titan
Castle Biosciences COO Kristen M. Oelschlager Exercises Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 6,577 Shares - GuruFocus
Castle Biosciences CCO Executes 6,577-Share Sale Under Rule 10b5-1 Plan - Kalkine Media
Officer Kristen Oelschlager proposes selling 4,153 Castle Biosciences (CSTL) shares. - stocktitan.net
Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com UK
Castle Biosciences CEO sells $512k in stock - Investing.com
Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com Nigeria
Castle Biosciences CEO sells $512k in stock By Investing.com - Investing.com Nigeria
Form 4 Castle Biosciences Inc For: 26 September By Investing.com - Investing.com India
Castle Biosciences (NASDAQ:CSTL) Upgraded to "Buy" at Wall Street Zen - marketbeat.com
How Investors May Respond To Castle Biosciences Stock After New Test Validation Studies - simplywall.st
Castle Biosciences (NASDAQ: CSTL) Chief Commercial Officer Juvenal Tobin W Sells 6,600 Shares Between $32.32 and $35.14 - Kalkine Media
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 6,600 Shares - GuruFocus
6,600 Castle Biosciences (CSTL) shares sold under preset 10b5-1 plan - Stock Titan
Castle Biosciences (CSTL) CCO plans more stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Preset sale plan at Castle Biosciences (CSTL) covers 29K shares - Stock Titan
Castle Biosciences, Inc.JAAD Publication Shows Improved Performance of DecisionDx-SCC - marketscreener.com
Responsive Playbooks and the CSTL Inflection - Stock Traders Daily
Castle Biosciences, Inc. (CSTL) Stock Price Quote Today & Current Price Chart - Capital.com
JAAD Publication Shows Improved Performance of DecisionDx®-SCC - AdVantageNews.com
CSTL Looks 8.4% Overvalued on GF Value™ - GuruFocus
SciBase receives additional order from Castle Biosciences, advancing the collaboration - Yahoo Finance
Bank of New York Mellon Corp Invests $2.34 Million in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences, Inc. $CSTL Shares Sold by Bank of America Corp DE - MarketBeat
Castle Biosciences COO Oelschlager sells $138,642 in shares By Investing.com - Investing.com Nigeria
Castle Biosciences COO Oelschlager sells $138,642 in shares - Investing.com
Castle Biosciences COO Oelschlager sells $138,642 in shares - Investing.com India
Castle Biosciences COO Oelschlager sells $138,642 in shares By Investing.com - Investing.com UK
Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares By Investing.com - Investing.com South Africa
Castle Biosciences (NASDAQ:CSTL) Beats Estimates As Momentum Builds - Kalkine Media
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 1,730 Shares - GuruFocus
Castle Biosciences (CSTL) Slips 2.4% to $32.62: Key Support in FocusNews Sentiment - vinanet.vn
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Castle Biosciences Inc-Aktie (CSTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Oct 19 '26 |
Sale |
31.91 |
5,916 |
188,780 |
4,114 |
| Tobin Juvenal | Chief Commercial Officer |
Oct 12 '26 |
Proposed Sale |
32.76 |
13,154 |
430,925 |
0 |
| Juvenal Tobin W | Chief Commercial Officer |
Oct 12 '26 |
Sale |
33.64 |
3,288 |
110,608 |
48,719 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Oct 05 '26 |
Sale |
35.57 |
8,580 |
305,156 |
21,064 |
| Derek Maetzold | Officer |
Oct 05 '26 |
Proposed Sale |
36.65 |
28,992 |
1,062,557 |
0 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Oct 05 '26 |
Option Exercise |
2.39 |
8,165 |
19,514 |
29,644 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Oct 05 '26 |
Sale |
35.57 |
5,916 |
210,408 |
6,832 |
| Oelschlager Kristen M | Chief Operating Officer |
Oct 01 '26 |
Option Exercise |
3.38 |
4,153 |
14,037 |
17,509 |
| KRISTEN OELSCHLAGER | Officer |
Oct 01 '26 |
Proposed Sale |
35.53 |
4,153 |
147,556 |
0 |
| Oelschlager Kristen M | Chief Operating Officer |
Oct 01 '26 |
Sale |
35.95 |
4,153 |
149,318 |
13,356 |
0.31%
4.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):